Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Photographer
|
| gptkbp:appointed_by |
intravenous injection
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:can_provide |
differentiating Parkinson's disease from other disorders
|
| gptkbp:contains |
gptkb:Ioflupane
|
| gptkbp:contraindication |
hypersensitivity to Ioflupane
|
| gptkbp:developed_by |
gptkb:GE_Healthcare
|
| gptkbp:has |
specific imaging protocols
|
| https://www.w3.org/2000/01/rdf-schema#label |
Da Tscan
|
| gptkbp:improves |
diagnostic accuracy
|
| gptkbp:indication |
patients with suspected Parkinsonian syndromes
|
| gptkbp:is |
gptkb:radio_station
non-invasive a diagnostic tool used in clinical trials a tool for research a diagnostic imaging agent a key component in Parkinson's disease management a method for evaluating neurotransmitter systems a non-invasive imaging technique a radiolabeled compound a significant advancement in neuroimaging a type of SPECT imaging a valuable diagnostic aid not a first-line test not a treatment part of differential diagnosis used in conjunction with clinical evaluation used to assess dopamine function used to assess treatment response used to confirm clinical diagnosis used to evaluate movement disorders used to monitor disease progression used to visualize brain activity |
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_used_by |
neurologists
|
| gptkbp:is_used_for |
diagnosing Parkinson's disease
|
| gptkbp:marketed_as |
gptkb:Ioflupane_I-123
|
| gptkbp:photography |
gptkb:SPECT
|
| gptkbp:recognizes |
dopamine transporters
|
| gptkbp:requires |
patient consent
specialized imaging equipment |
| gptkbp:side_effect |
dizziness
fatigue headache nausea |
| gptkbp:suitable_for |
pregnant women
nursing mothers |
| gptkbp:used_in |
nuclear medicine
|
| gptkbp:bfsParent |
gptkb:Parkinson's_Disease
|
| gptkbp:bfsLayer |
6
|